LG Life Sciences Wins Exclusive Marketing Right for AMEVIVE

Published: 2004-12-02 06:57:00

Updated: 2004-12-02 06:57:00

LG Life Sciences, Ltd. and Biogen Idec Inc., a U.S.-based biotechnology company, have recently agreed to make LG Life Sciences an exclusive marketing partner for sale of Biogen’s AMEVIVE (Alefacept) in Korea.

AMEVIVE is the first biological medication approved by the U.S. FDA back in January o...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK